NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$12.31
+0.45 (+3.79%)
Financial Highlights (FY 2026)
Revenue
79.96M
Net Income
-487,654,583
Gross Margin
—
Profit Margin
-609.9%
Rev Growth
+9.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 47.2% | 47.2% |
| Operating Margin | -651.7% | -586.5% | -16.3% | -17.5% |
| Profit Margin | -609.9% | -579.4% | -13.6% | -13.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 79.96M | 73.30M | 223.20M | 196.34M |
| Gross Profit | — | — | 105.32M | 92.65M |
| Operating Income | -521,081,900 | -429,896,149 | -36,318,767 | -34,359,138 |
| Net Income | -487,654,583 | -402,318,383 | -30,251,127 | -26,608,774 |
| Gross Margin | — | — | 47.2% | 47.2% |
| Operating Margin | -651.7% | -586.5% | -16.3% | -17.5% |
| Profit Margin | -609.9% | -579.4% | -13.6% | -13.6% |
| Rev Growth | +9.1% | +9.1% | +19.1% | +20.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 735.97M | 562.69M |
| Total Equity | — | — | 1.00B | 1.02B |
| D/E Ratio | — | — | 0.73 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -509,552,937 | -443,739,380 | -52,265,042 | -37,903,322 |
| Free Cash Flow | — | — | -47,461,783 | -26,029,407 |